title: Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study.
abstract: BACKGROUND
  Neuroinflammation and demyelination have been suggested as mechanisms causing HIV-1 associated neurocognitive disorder (HAND). This cross-sectional cohort study explores the potential role of antibodies to myelin oligodendrocyte glycoprotein (MOG), a putative autoantigen in multiple sclerosis, in the pathogenesis of HAND.
  
  
  METHODS
  IgG antibodies against MOG were measured by ELISA in sera and cerebrospinal fluid (CSF) of 65 HIV-positive patients with HAND (n = 14), cerebral opportunistic infections (HIVOI, n = 25), primary HIV infection (HIVM, n = 5) and asymptomatic patients (HIVasy, n = 21). As control group HIV-negative patients with bacterial or viral CNS infections (OIND, n = 18) and other neurological diseases (OND, n = 22) were included. In a subset of HAND patients MOG antibodies were determined before and during antiviral therapy.
  
  
  RESULTS
  In serum, significantly higher MOG antibody titers were observed in HAND compared to OND patients. In CSF, significantly higher antibody titers were observed in HAND and HIVOI patients compared to HIVasy and OND patients and in OIND compared to OND patients. CSF anti-MOG antibodies showed a high sensitivity and specificity (85.7% and 76.2%) for discriminating patients with active HAND from asymptomatic HIV patients. MOG immunopositive HAND patients performed significantly worse on the HIV dementia scale and showed higher viral load in CSF. In longitudinally studied HAND patients, sustained antibody response was noted despite successful clearance of viral RNA.
  
  
  CONCLUSIONS
  Persistence of MOG antibodies despite viral clearance in a high percentage of HAND patients suggests ongoing neuroinflammation, possibly preventing recovery from HAND.
authors.affiliation: Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. peter.lackner@i-med.ac.at
authors.forename: Peter
authors.initials: P
authors.lastname: Lackner
authors.forename: Bettina
authors.initials: B
authors.lastname: Kuenz
authors.forename: Markus
authors.initials: M
authors.lastname: Reindl
authors.forename: Maria
authors.initials: M
authors.lastname: Morandell
authors.forename: Thomas
authors.initials: T
authors.lastname: Berger
authors.forename: Erich
authors.initials: E
authors.lastname: Schmutzhard
authors.forename: Christian
authors.initials: C
authors.lastname: Eggers
mesh_terms: D015526:AIDS Dementia Complex / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000276:immunology; D001921:Brain / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000276:immunology; D008875:Middle Aged; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D012367:RNA, Viral / Q000097:blood; D012680:Sensitivity and Specificity; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D001323:Autoantibodies; C571326:MOG protein, human; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D012367:RNA, Viral